Radiopharm Theranostics (ASX:RAD) Operating Margin %: -659.67% (As of Jun. 2025)


What is Radiopharm Theranostics Operating Margin %?

Radiopharm Theranostics ASX:RAD -5.00% Operating Margin % is -659.67% as of Jun. 2025. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Radiopharm Theranostics ranks worse than 78.2% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Radiopharm Theranostics's Operating Income for the six months ended in Jun. 2025 was A$-14.84 Mil. Radiopharm Theranostics's Revenue for the six months ended in Jun. 2025 was A$2.25 Mil. Therefore, Radiopharm Theranostics's Operating Margin % for the quarter that ended in Jun. 2025 was -659.67%.

The historical rank and industry rank for Radiopharm Theranostics's Operating Margin % or its related term are showing as below:

ASX:RAD' s Operating Margin % Range Over the Past 10 Years
Min: -221288.89   Med: -11642.93   Max: -953.51
Current: -953.51


ASX:RAD's Operating Margin % is ranked worse than
78.2% of 945 companies
in the Biotechnology industry
Industry Median: -86.77 vs ASX:RAD: -953.51

Radiopharm Theranostics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Radiopharm Theranostics's Operating Income for the six months ended in Jun. 2025 was A$-14.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2025 was A$-34.64 Mil.

Warning Sign:

Radiopharm Theranostics Ltd has never been profitable in the past 3 years. It lost money every year.


Radiopharm Theranostics  (ASX:RAD) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Radiopharm Theranostics Operating Margin % Related Terms


Radiopharm Theranostics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Operating Margin % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Operating Margin %
-221,288.89 -10,853.08 -12,432.78 -953.51

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Operating Margin % Get a 7-Day Free Trial 0.00 0.00 -6,055.85 -1,431.00 -659.67

ASX:RAD vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Operating Margin % falls into.



Radiopharm Theranostics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Radiopharm Theranostics's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as

Operating Margin %=Operating Income (A: Jun. 2025 ) / Revenue (A: Jun. 2025 )
=-34.641 / 3.633
=-953.51 %

Radiopharm Theranostics's Operating Margin % for the quarter that ended in Jun. 2025 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2025 ) / Revenue (Q: Jun. 2025 )
=-14.836 / 2.249
=-659.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -659.67% mean?
Radiopharm Theranostics (ASX:RAD) has a Operating Margin % of -659.67% as of Jun. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Radiopharm Theranostics and its competitors. According to the industry distribution chart, Radiopharm Theranostics ranks #739 out of 945 companies in the Biotechnology industry, placing it in the top 78.2%.
Is Radiopharm Theranostics' Operating Margin % too high?
Radiopharm Theranostics' current Operating Margin % is -659.67%. Based on the distribution chart, Radiopharm Theranostics ranks #739 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #739 out of 945 companies for Operating Margin %. This places Radiopharm Theranostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Operating Margin % is -659.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Operating Margin % of -659.67%. The current Operating Margin % is -659.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Operating Margin % is -659.67% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.